4346 related articles for article (PubMed ID: 12739251)
21. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.
Koeppen H; Acena M; Drolet A; Rowley DA; Schreiber H
Eur J Immunol; 1993 Nov; 23(11):2770-6. PubMed ID: 8223853
[TBL] [Abstract][Full Text] [Related]
22. Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction.
Paroli M; Carloni G; Franco A; De Petrillo G; Alfani E; Perrone A; Barnaba V
Immunology; 1994 Jun; 82(2):215-21. PubMed ID: 7927492
[TBL] [Abstract][Full Text] [Related]
23. Soluble factors produced during an immune response regulate Ia antigen expression by murine adenocarcinoma and fibrosarcoma cells.
Callahan GN
J Immunol; 1984 May; 132(5):2649-57. PubMed ID: 6201554
[TBL] [Abstract][Full Text] [Related]
24. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
25. Role of interferon-gamma in T-cell responses to Semliki Forest virus-infected murine brain cells.
Tomkins PT; Ward GA; Morris AG
Immunology; 1988 Mar; 63(3):355-62. PubMed ID: 2832313
[TBL] [Abstract][Full Text] [Related]
26. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal c-myc transformed macrophage cell lines. I. Heterogeneity in ability to process and present antigen.
Trannoy E; Manser T; Cole MD; Daley MJ
J Immunol; 1993 Sep; 151(6):3042-56. PubMed ID: 8104218
[TBL] [Abstract][Full Text] [Related]
28. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
29. Ontogeny of MHC-linked, T cell-mediated suppression is regulated by the T cell genotype.
Araneo BA
J Mol Cell Immunol; 1986; 2(4):219-31. PubMed ID: 2855403
[TBL] [Abstract][Full Text] [Related]
30. The syngeneic T-T lymphocyte reaction (STTLR). II. Induction of primary T anti-T cell cytotoxic responses in vitro in T cell cultures stimulated with syngeneic self-reactive T cells.
Suzuki H; Quintáns J
J Mol Cell Immunol; 1986; 2(6):345-57. PubMed ID: 3509919
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of mouse T lymphocyte-induced suppression of the IgG2ab allotype and T lymphocyte tolerance to IgG2ab.
Majlessi L; Bordenave G
Arch Immunol Ther Exp (Warsz); 2001; 49(6):407-15. PubMed ID: 11814234
[TBL] [Abstract][Full Text] [Related]
32. Formation of complexes between self-peptides and MHC class II molecules in cells defective for presentation of exogenous protein antigens.
Bikoff EK
J Immunol; 1992 Jul; 149(1):1-8. PubMed ID: 1318896
[TBL] [Abstract][Full Text] [Related]
33. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
34. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M; Pfeifer J; Stockinger B; Wick MJ
Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
36. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
[TBL] [Abstract][Full Text] [Related]
37. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
38. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
39. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
40. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
